NASDAQ:DSGN Design Therapeutics (DSGN) Stock Price, News & Analysis $4.65 -0.06 (-1.27%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$4.66 +0.00 (+0.11%) As of 05/2/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Design Therapeutics Stock (NASDAQ:DSGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Design Therapeutics alerts:Sign Up Key Stats Today's Range$4.64▼$4.9450-Day Range$2.79▼$5.3352-Week Range$2.60▼$7.77Volume63,554 shsAverage Volume202,517 shsMarket Capitalization$263.95 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingModerate Buy Company OverviewDesign Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Read More… Design Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreDSGN MarketRank™: Design Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 823rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingDesign Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDesign Therapeutics has received no research coverage in the past 90 days.Read more about Design Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Design Therapeutics are expected to decrease in the coming year, from ($0.91) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Design Therapeutics is -5.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Design Therapeutics is -5.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDesign Therapeutics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Design Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.24% of the float of Design Therapeutics has been sold short.Short Interest Ratio / Days to CoverDesign Therapeutics has a short interest ratio ("days to cover") of 23.9, which indicates bearish sentiment.Change versus previous monthShort interest in Design Therapeutics has recently increased by 4.52%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDesign Therapeutics does not currently pay a dividend.Dividend GrowthDesign Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.24% of the float of Design Therapeutics has been sold short.Short Interest Ratio / Days to CoverDesign Therapeutics has a short interest ratio ("days to cover") of 23.9, which indicates bearish sentiment.Change versus previous monthShort interest in Design Therapeutics has recently increased by 4.52%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Design Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Design Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Design Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Design Therapeutics' insider trading history. Receive DSGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DSGN Stock News HeadlinesDesign Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025May 3 at 6:18 PM | nasdaq.comDesign Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal DystrophyMay 1 at 8:00 AM | globenewswire.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 4, 2025 | Golden Portfolio (Ad)Design Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025April 22, 2025 | nasdaq.comDesign Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025April 21, 2025 | globenewswire.comDesign Therapeutics appoints Chris Storgard as CMOApril 19, 2025 | markets.businessinsider.comDesign Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical OfficerApril 17, 2025 | globenewswire.comBright Peak Therapeutics Appoints John Schmid to its Board of DirectorsApril 17, 2025 | markets.businessinsider.comSee More Headlines DSGN Stock Analysis - Frequently Asked Questions How have DSGN shares performed this year? Design Therapeutics' stock was trading at $6.17 at the beginning of 2025. Since then, DSGN stock has decreased by 24.6% and is now trading at $4.65. View the best growth stocks for 2025 here. How were Design Therapeutics' earnings last quarter? Design Therapeutics, Inc. (NASDAQ:DSGN) issued its earnings results on Monday, March, 10th. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.04. When did Design Therapeutics IPO? Design Therapeutics (DSGN) raised $228 million in an initial public offering on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler served as the underwriters for the IPO. Who are Design Therapeutics' major shareholders? Top institutional investors of Design Therapeutics include Palumbo Wealth Management LLC (0.10%), Rhumbline Advisers (0.08%) and Assenagon Asset Management S.A. (0.07%). Insiders that own company stock include Sr One Capital Fund I Aggregat, Simeon George, Rodney W Lappe, Joao Md Siffert, John P Schmid, Deepa Prasad and Arsani William. View institutional ownership trends. How do I buy shares of Design Therapeutics? Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Design Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Design Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings3/10/2025Today5/04/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DSGN CIK1807120 Webwww.designtx.com Phone858-293-4900FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$12.00 Low Stock Price Target$4.00 Potential Upside/Downside+72.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-18.01% Return on Assets-17.38% Debt Debt-to-Equity RatioN/A Current Ratio34.61 Quick Ratio34.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.96 per share Price / Book0.94Miscellaneous Outstanding Shares56,763,000Free Float38,955,000Market Cap$263.95 million OptionableOptionable Beta1.82 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:DSGN) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredWhy Elon put $51 million into thisWhile fear dominates the headlines, a silent breakthrough could turn panic into profit. The future of AI fa...True Market Insiders | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.